Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Medicinova Inc (NQ: MNOV)
9.255 USD  +0.275 (+3.06%)
Streaming Delayed Price  /  Updated: 3:24 PM EDT, Aug 21, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 44,003
Open 9.050
Bid (Size) 9.210 (3)
Ask (Size) 9.250 (10)
Prev. Close 8.980
Today's Range 9.020 - 9.290
52wk Range 4.780 - 14.50
Shares Outstanding 41,129,073
Dividend Yield N/A
Performance
YTD
+40.23%
+40.23%
1 Month
+9.53%
+9.53%
3 Month
-6.33%
-6.33%
6 Month
-15.94%
-15.94%
1 Year
+86.22%
+86.22%
Top News
More News
National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National... Read More
from GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, Inc.... Read More
from GlobeNewswire News Releases
More News
Read More
MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
from GlobeNewswire News Releases
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
from GlobeNewswire News Releases
MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
from GlobeNewswire News Releases
Drug Developers Expecting Significant Clinical and Economic Benefits by Targeting Newest Drug Therapies
from PR Newswire
MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS
from GlobeNewswire News Releases
MNOV Crosses Below Key Moving Average Level
category Stocks
from Market News Video
IEIH's Underlying Holdings Could Mean 16% Gain Potential
category ETFs
from ETF Channel
Commit To Buy Medicinova At $7.50, Earn 13.4% Annualized Using Options
category Stocks
from Market News Video
Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Expectations
category BLIN , STAF , Eurozone , and 15 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.